Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DV3C | ISIN: US92536C1036 | Ticker-Symbol: FMW
Tradegate
20.05.24
08:12 Uhr
1,238 Euro
+0,037
+3,08 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VERU INC Chart 1 Jahr
5-Tage-Chart
VERU INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2181,25308:19
1,2181,25308:13

Aktuelle News zur VERU Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiVeru Inc.: Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss3
DiVeru Inc.: Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week2
08.05.VERU INC. - 10-Q, Quarterly Report3
08.05.VERU INC. - 8-K, Current Report3
08.05.Veru GAAP EPS of -$0.07 misses by $0.01, revenue of $4.14B beats by $4.14B5
08.05.Veru Inc.: Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program192--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific...
► Artikel lesen
06.05.Critical Insights From Veru Analyst Ratings: What You Need To Know10
02.05.Veru Inc.: Veru to Present at the GLP-1 Based Therapeutics Summit11
01.05.Veru Inc.: Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 20246
30.04.Veru Inc.: Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss175-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024...
► Artikel lesen
25.04.Veru Inc.: Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-117
25.04.VERU INC. - 8-K, Current Report4
19.04.LI, VERU and MRIN among pre-market losers11
18.04.Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers40
12.04.Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers38
11.04.NKTR, VERU and EGIO among mid-day movers90
01.04.VERU INC. - 10-Q, Quarterly Report64
01.04.VERU INC. - 10-K/A, Annual Report24
22.03.Veru Inc.: Veru Reschedules Annual Meeting of Shareholders26
12.03.Veru Inc.: Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss17
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4